Response to parenteral iron with and without androgen therapy in patients undergoing regular haemodialysis.
The effects of intravenous iron, with and without androgens, was studied in a group of 39 patients treated by regular haemodialysis, almost all of whom had normal serum iron concentrations. Intravenous iron 1-2 g every 4 months produced a significant rise in haemoglobin from 6.3 to 7.9 g/dl in 17 female patients with their kidneys in situ (p less than 0.001). In a group of 13 male subjects intravenous iron plus testosterone produced a similar rise in haemoglobin from 6.9 to 8.6 g/dl (p less than 0.001). Nine nephrectomised patients showed no significant response to iron and androgens. There were no fatalities and no serious side effects in 500 courses of intravenous iron.
D000740:Anemia / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D007267:Injections; D007501:Iron / Q000009:adverse effects / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000628:therapy*; D008297:Male; D009392:Nephrectomy; D006435:Renal Dialysis; D013739:Testosterone / Q000009:adverse effects / Q000627:therapeutic use*; D014511:Uremia / Q000628:therapy
D013739:Testosterone; D007501:Iron